Stoke Therapeutics, Inc. (STOK) saw its stock price soar 5.39% during intraday trading on Friday.
The surge follows a significant analyst action, as Canaccord Genuity raised its price target for the company to $60 from $36, representing a substantial vote of confidence in the biotech firm's outlook.
Broader Wall Street optimism was also noted, with multiple analysts recently expressing bullish views on Stoke Therapeutics among other healthcare picks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.